Plasma Norepinephrine Predicts Survival and Incident Cardiovascular Events in Patients With End-Stage Renal Disease
Carmine Zoccali(Biogem), Lorenzo Malatino(University of Catania), Pasquale Fatuzzo(University of Catania), Francesca Mallamaci(Società Italiana di Nefrologia), Alessandro Cataliotti(University of Catania), Sebastiano Cutrupi(National Research Council), Francesco Benedetto(Ospedale Eugenio Morelli), Benedetta Stancanelli(Ospedale Eugenio Morelli), Saverio Parlongo(National Research Council), Giuseppe Seminara(University of Catania), Francesco Rapisarda(University of Catania), Graziella Bonanno(University of Catania), Giovanni Tripepi(National Research Council)
Cited by 522
Related Papers
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
|American Journal of Nephrology|2017|2.2k
Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study
|The Lancet|2001|1.1k
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
|The Lancet|1999|909
A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases
|Kidney International|2019|886
An introduction to inverse probability of treatment weighting in observational research
|Clinical Kidney Journal|2021|877